Trial reportCurrent oncology (Toronto, Ont.)2022
Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
Open access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase IIIEquivalence Trial
In one paragraph
Trial report in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Pooled it
- Transcatheter arterial chemoembolization combined with stereotactic body radiation therapy versus transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma.Clinical and molecular hepatology · 2025Guideline
- Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.JAMA network open · 2024Pooled it
- Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2023Pooled it
- VMAT-based lattice radiotherapy for advanced bulky hepatocellular carcinoma within multimodality treatment: a consecutive feasibility series.Clinical and translational radiation oncology · 2026Article
- Daily image-guided carbon ion stereotactic radiotherapy of hepatocellular carcinoma: paving the way for MR-guided online adaptive treatment.Radiation oncology (London, England) · 2026Article
- Stereotactic body radiation therapy for hepatocellular carcinoma: 2026 expert consensus-based practical recommendation of the Korean Liver Cancer Association.Radiation oncology journal · 2026Article
- Stereotactic body radiation therapy for hepatocellular carcinoma: 2026 expert consensus-based practical recommendation of the Korean Liver Cancer Association.Journal of liver cancer · 2026Article
- From practical consensus to clinical integration: positioning stereotactic body radiation therapy in the contemporary management of hepatocellular carcinoma.Journal of liver cancer · 2026Article
- Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization.ESMO gastrointestinal oncology · 2026Article
- External beam radiation for HCC: Ready for incorporation into guidelines?JHEP reports : innovation in hepatology · 2026Review
- Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis.Frontiers in immunology · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Article
- SBRT for bridging and downstaging HCC before transplant.JHEP reports : innovation in hepatology · 2025Article
- Long-Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma.Cancer reports (Hoboken, N.J.) · 2025Article
- Evaluation and Management of Unresectable Hepatocellular Carcinoma: Multidisciplinary Indian Consensus Statements from a Delphi Panel.South Asian journal of cancer · 2025Review
- Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Tiziana ComitoRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Mauro LoiRadiation Oncology Unit, Azienda Ospedaliero Universitaria Careggi, 50134 Florence, Italy.
Ciro FranzeseRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.ORCID 0000-0001-6893-6284
Elena ClericiRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Davide FranceschiniRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.ORCID 0000-0003-1142-2439
Marco BadalamentiRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Maria Ausilia TeriacaRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Lorenza RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.ORCID 0000-0001-9957-3615
Vittorio PediciniDepartment of Radiology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Dario PorettiDepartment of Radiology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Luigi Alessandro SolbiatiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
Guido TorzilliDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.ORCID 0000-0001-5798-5021
Roberto CerianiDepartment of Hepatology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Ana LleoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.ORCID 0000-0002-0561-7902
Alessio AghemoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
Armando SantoroDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
Marta ScorsettiRadiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Humanitas University · ITIRCCS Humanitas Research Hospital · ITAzienda Ospedaliero-Universitaria Careggi · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsRadiosurgeryHumansNeoplasm Recurrence, LocalProspective StudiesRetrospective Studiesablative therapyBCLCclinical trialHCCliver neoplasmslocal treatmentradiotherapySBRTTACETAE
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.